Bayer in pact with Acuitas to bolster gene therapy pipeline

• Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) has inked a partnership with Acuitas Therapeutics, Inc. to access Canadian biotech's lipid nanoparticle (LNP) delivery technology to strengthen its gene therapy portfolio further.
• Per the terms, the German conglomerate will leverage Acuitas' ionizable lipid technology and LNP carriers to direct gene-editing RNA components to the targeted organ, the liver.
• The partnership is expected to accelerate the advancement of first in vivo gene editing programs developed by Bayer (OTCPK:BAYZF) and its gene therapy unit AskBio into clinical development. Financial details of the agreement were not disclosed.
• "Accessing state-of-the-art LNP technology through this collaboration will add momentum to our gene editing efforts for the benefit of patients," said Friedemann Janus, acting chief of Business Development and Licensing at Bayer's (OTCPK:BAYZF) pharma division.

More on Bayer

• Bayer inks licensing deal with Cedilla to boost oncology pipeline
• Bayer AG Still Dirt-Cheap, Investors Are Getting Its Pharma Business For 'Free'